Search research articles
Contact Us
Filters
Showing results (81-90 of 138) with videos related to
Page
of 14
Sort By:
The Journal of Investigative Dermatology
|
August 8, 2013
Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress
Amanda Croft, Kwang H Tay, Suzanah C Boyd, et al.
BMC Genomics
|
November 30, 2012
A parallel genome-wide mRNA and microRNA profiling of the frontal cortex of HIV patients with and without HIV-associated dementia shows the role of axon guidance and downstream pathways in HIV-mediated neurodegeneration
Li Zhou, Gulietta M Pupo, Priyanka Gupta, et al.
Biomacromolecules
|
April 19, 2019
Label-Free Fluorescent Poly(amidoamine) Dendrimer for Traceable and Controlled Drug Delivery
Guoying Wang, Libing Fu, Adam Walker, et al.
Frontiers in Oncology
|
May 2, 2022
Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
Russell J Diefenbach, Jenny H Lee, Ashleigh Stewart, et al.
Molecular Cancer
|
January 20, 2009
The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a
Therese M Becker, Sebastian Haferkamp, Menno K Dijkstra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients
Matteo S Carlino, Carina Fung, Hamideh Shahheydari, et al.
Pigment Cell & Melanoma Research
|
June 14, 2014
Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151
Stuart J Gallagher, Branka Mijatov, Dilini Gunatilake, et al.
Molecular Cancer Therapeutics
|
May 7, 2013
Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma
Matteo S Carlino, Kavitha Gowrishankar, Catherine A B Saunders, et al.
Molecular Cancer
|
October 11, 2024
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response
Su Yin Lim, Ines Pires da Silva, Nurudeen A Adegoke, et al.
Cellular Signalling
|
May 30, 2015
The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function
Varsha Tembe, Estefania Martino-Echarri, Kamila A Marzec, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 138) with videos related to
Sort By:
Page
of 14
The Journal of Investigative Dermatology
|
August 8, 2013
Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress
Amanda Croft, Kwang H Tay, Suzanah C Boyd, et al.
BMC Genomics
|
November 30, 2012
A parallel genome-wide mRNA and microRNA profiling of the frontal cortex of HIV patients with and without HIV-associated dementia shows the role of axon guidance and downstream pathways in HIV-mediated neurodegeneration
Li Zhou, Gulietta M Pupo, Priyanka Gupta, et al.
Biomacromolecules
|
April 19, 2019
Label-Free Fluorescent Poly(amidoamine) Dendrimer for Traceable and Controlled Drug Delivery
Guoying Wang, Libing Fu, Adam Walker, et al.
Frontiers in Oncology
|
May 2, 2022
Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
Russell J Diefenbach, Jenny H Lee, Ashleigh Stewart, et al.
Molecular Cancer
|
January 20, 2009
The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a
Therese M Becker, Sebastian Haferkamp, Menno K Dijkstra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients
Matteo S Carlino, Carina Fung, Hamideh Shahheydari, et al.
Pigment Cell & Melanoma Research
|
June 14, 2014
Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151
Stuart J Gallagher, Branka Mijatov, Dilini Gunatilake, et al.
Molecular Cancer Therapeutics
|
May 7, 2013
Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma
Matteo S Carlino, Kavitha Gowrishankar, Catherine A B Saunders, et al.
Molecular Cancer
|
October 11, 2024
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response
Su Yin Lim, Ines Pires da Silva, Nurudeen A Adegoke, et al.
Cellular Signalling
|
May 30, 2015
The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function
Varsha Tembe, Estefania Martino-Echarri, Kamila A Marzec, et al.
Page
of 14